Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in Multicentric Castleman’s Disease – Long-term Safety
CTR20132662Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in multicentric angiofollicular lymphoid hyperplasia (MCD), sponsored by Janssen Pharmaceutical. Started Jan 2015; status: completed.
02
Drugs
siltuximab
03
Conditions
multicentric angiofollicular lymphoid hyperplasia (MCD)
Beyond the preview
Go deeper on CTR20132662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132662.